Home › Funds › NEW SOUTH CAPITAL MANAGEMENT INC › RPRX

NEW SOUTH CAPITAL MANAGEMENT INC position in RPRX

ROYALTY PHARMA PLC · Health Care

NEW SOUTH CAPITAL MANAGEMENT INC reported holding 1,445,493 shares of RPRX (ROYALTY PHARMA PLC) in its Q3 2026 13F filing — a position valued at US$84.4M, representing 5.50% of its reported portfolio and ranking #5 among its reported holdings. NEW SOUTH CAPITAL MANAGEMENT INC has disclosed RPRX holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

Latest position (Q3 2026)1.45M sh
Reported value held$84.36M
Portfolio Weight5.50%
First reportedQ1 2024
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How NEW SOUTH CAPITAL MANAGEMENT INC's RPRX position evolved

NEW SOUTH CAPITAL MANAGEMENT INC first disclosed a stake in RPRX in Q1 2024 at 1,461,455 shares (US$44.4M). The position peaked in Q2 2026 at 2,385,943 shares, worth US$133.8M. Across 11 filings, NEW SOUTH CAPITAL MANAGEMENT INC increased the stake 4 time(s), trimmed it 5 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 1,445,493 shares valued at US$84.4M — a reduction of -940,450 shares quarter over quarter.. Notable position changes include a 61% increase in Q2 2024 (shares rose 7% over the following quarter), a 39% trim in Q3 2026 (shares rose 19% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 1.46M $44.38M New
Q2 2024 2.35M $61.94M Add
Q3 2024 2.47M $69.77M Add
Q4 2024 2.96M $75.44M Add
Q1 2025 2.91M $90.51M Reduce
Q2 2025 2.89M $104.00M Reduce
Q3 2025 2.92M $102.96M Add
Q4 2025 2.93M $113.17M Hold
Q1 2026 2.63M $125.96M Reduce
Q2 2026 2.39M $133.78M Reduce
Q3 2026 1.45M $84.36M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RPRX and 13F data

RPRX (ROYALTY PHARMA PLC) is a Health Care company. 47 other funds we track also report a position in RPRX — the largest reported positions include Swedbank AB (US$598.8M), Baillie Gifford & Co (US$534.1M), ROYAL LONDON ASSET MANAGEMENT LTD (US$348.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RPRX

All RPRX fund holders →

FAQ

How long has NEW SOUTH CAPITAL MANAGEMENT INC held RPRX?

NEW SOUTH CAPITAL MANAGEMENT INC has disclosed RPRX holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

What is NEW SOUTH CAPITAL MANAGEMENT INC's current position in RPRX?

As of Q3 2026, NEW SOUTH CAPITAL MANAGEMENT INC holds 1.45M shares of RPRX (ROYALTY PHARMA PLC), valued at $84.36M, representing 5.50% of its reported portfolio and ranking #5.

Has NEW SOUTH CAPITAL MANAGEMENT INC been buying or selling RPRX?

In the latest 13F filing (Q3 2026), NEW SOUTH CAPITAL MANAGEMENT INC reduced its position in RPRX. The position peaked in Q2 2026 at 2.39M shares.

Which other funds hold RPRX?

Other major institutional holders of RPRX include Swedbank AB, Baillie Gifford & Co, ROYAL LONDON ASSET MANAGEMENT LTD, among 47 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.